Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price
Cognition Therapeutics (NASDAQ:CGTX – Free Report) had its price objective decreased by Chardan Capital from $11.00 to $8.00 in a research note released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock. CGTX has been the subject of a number of other research reports. B. Riley raised shares of Cognition […]
Cognition Therapeutics (NASDAQ:CGTX – Free Report) had its price objective decreased by Chardan Capital from $11.00 to $8.00 in a research note released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock. CGTX has been the subject of a number of other research reports. B. Riley raised shares of Cognition […]
